Intra-Cellular Therapies
ITCI65
$126.20arrow_drop_down0.07%-$0.09
ITCI65
$126.20
arrow_drop_down0.07%Performance History
| Key Stats | |
|---|---|
| Open | $126.65 |
| Prev. Close | $126.26 |
| EPS | -0.87 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 126.16 | 127.22 |
| 52 Week Range | 45.50 | 128.92 |
| Ratios | |
|---|---|
| EPS | -0.87 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Intra-Cellular Therapies (ITCI)
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- CEO
- Dr. Sharon Mates Ph.D.
- Headquarters
- New York
- Employees
- 561
- Exchange
- NASDAQ
Keep an eye on Intra-Cellular Therapies
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Intra-Cellular Therapies 's (ITCI) price per share?
The current price per share for Intra-Cellular Therapies (ITCI) is $126.2. The stock has seen a price change of -$0.09 recently, indicating a -0.07% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Intra-Cellular Therapies (ITCI)?
For Intra-Cellular Therapies (ITCI), the 52-week high is $128.92, which is 2.16% from the current price. The 52-week low is $45.5, the current price is 177.36% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Intra-Cellular Therapies (ITCI) a growth stock?
Intra-Cellular Therapies (ITCI) has shown an average price growth of 2.34% over the past three years. It has received a score of 87 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Intra-Cellular Therapies as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Intra-Cellular Therapies (ITCI) stock price performance year to date (YTD)?
As of the latest data, Intra-Cellular Therapies (ITCI) has a year-to-date price change of 51.1%. Over the past month, the stock has experienced a price change of 49.99%. Over the last three months, the change has been 64.09%. Over the past six months, the figure is 68.58%. Looking at a longer horizon, the five-year price change stands at 396.26%.
help
Is Intra-Cellular Therapies (ITCI) a profitable company?
Intra-Cellular Therapies (ITCI) has a net income of -$139.67M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 92.73% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -22.15% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $464.37M, with a revenue growth rate of 86.4%, providing insight into the company's sales performance and growth. The gross profit is $430.62M. Operating income is noted at -$159.38M. Furthermore, the EBITDA is -$121.09M.
help
What is the market capitalization of Intra-Cellular Therapies (ITCI)?
Intra-Cellular Therapies (ITCI) has a market capitalization of $13.41B. The average daily trading volume is 126.31, indicating the stock's liquidity and investor engagement.